Table 11 |
||
|
Other reported adverse events |
||
|
Condition |
Observations |
Treatment |
|
|
||
|
Hypertension |
1 |
UP446 250 mg |
|
Varicose veins |
1 |
UP446 250 mg |
|
Fluid in knee |
1 |
UP446 250 mg |
|
Reduced flexibility |
1 |
Placebo |
|
Psoriasis |
2 |
UP446 250 and 500 mg |
|
|
||
|
Sampalis and Brownell Nutrition Journal 2012 11:21 doi:10.1186/1475-2891-11-21 |
||
